A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorSinocelltech Ltd.
About this trial
The purpose of this study is to evaluate the safety and efficacy of SCTC21C in patients with CD38+ hematologic malignancies
Eligibility criteria
Qualifiers
Male or female aged ≥ 18 years old when signing ICF, weight ≥ 40 kg, ≤ 90 kg
Relapsed or refractory CD38+（confirmed by immunohistochemistry or flow cytometry） hematologic malignancies
Standard therapies failed or are unavailable or intolerant
Participants have at least one of the measurable lesions
Disqualifiers
A history of allergic reactions to any SCTC21C injection or any excipients, or Participants with a history of severe drug allergy
Participants who have other antineoplastic drug (except hormones) or radiotherapy within four weeks prior to the first dose of study drug, or the participants who have received immunotherapy or anti-CD38 monoclonal antibody within 6 months
Adverse events from the previous treatment have not resolved to ≤ Grade 1
Participants with prior immunotherapy and Grade ≥ 3 cytokine release syndrome(CRS)
Trial design
Treatments tested in this trial
- SCTC21C
Treatment groups
74 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov